ClinicalTrials.Veeva

Menu

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors (RIMRA)

D

Diakonhjemmet Hospital

Status

Active, not recruiting

Conditions

Immune-related Adverse Event

Treatments

Other: Antiinflammatory/DMARDs

Study type

Observational

Funder types

Other

Identifiers

NCT05544292
DS 00469

Details and patient eligibility

About

RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • De novo symptoms of rheumatic disease or a flare of established rheumatic disease after >/= 1 dose of treatment with an immune check point inhibitor
  • Adult patients (> 18 years)
  • Subject capable of understanding and signing an informed consent form

Exclusion criteria

• Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult

Trial contacts and locations

5

Loading...

Central trial contact

Marte S Heiberg, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems